Reversal of tolerance to morphine but no potentiation of morphine-induced analgesia by antiserum against cholecystokinin octapeptide
- PMID: 3491337
- DOI: 10.1016/0028-3908(86)90164-4
Reversal of tolerance to morphine but no potentiation of morphine-induced analgesia by antiserum against cholecystokinin octapeptide
Abstract
Tolerance to morphine analgesia was induced in rats by chronic treatment with morphine (5-30 mg/kg, t.i.d. for 6 days). Intracerebroventricular (i.c.v.) injection of antiserum against cholecystokinin octapeptide (CCK-8) reversed tolerance to morphine by 50% (P less than 0.001). Intrathecal (ith) injection of the CCK-8 antiserum produced a similar, although less marked, reversal of tolerance to morphine. Rats made tolerant to analgesia induced by morphine developed a cross tolerance to electroacupuncture-induced analgesia. This cross tolerance was also reversed by the CCK-8 antiserum by more than 50% (P less than 0.001). Intracerebroventricular or intrathecal injection of the CCK-8 antiserum per se produced no significant changes in the basal level of the latency of the tail flick response, nor did it affect the analgesia induced by morphine in naive rats. The results suggest that prolonged activation of opioid receptors may trigger the CCK-8 system in the central nervous system to exert a negative feedback control, which may constitute one of the mechanisms for the development of tolerance to opioids.
Similar articles
-
Cholecystokinin octapeptide (CCK-8): antagonism to electroacupuncture analgesia and a possible role in electroacupuncture tolerance.Pain. 1986 Oct;27(1):101-115. doi: 10.1016/0304-3959(86)90227-7. Pain. 1986. PMID: 3491355
-
Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of mu-opioid analgesia by CCKB receptor antagonist L-365,260 in rat spinal cord.Eur J Pharmacol. 1993 Apr 6;234(2-3):147-54. doi: 10.1016/0014-2999(93)90948-h. Eur J Pharmacol. 1993. PMID: 8387008
-
Is cholecystokinin octapeptide (CCK-8) a candidate for endogenous anti-opioid substrates?Neuropeptides. 1985 Feb;5(4-6):399-402. doi: 10.1016/0143-4179(85)90038-1. Neuropeptides. 1985. PMID: 4000412
-
[Interactions between central opioidergic and cholecystokininergic systems in rats: possible significance for the development of of opioid tolerance].Bull Acad Natl Med. 1998;182(2):311-24. Bull Acad Natl Med. 1998. PMID: 9648346 Review. French.
-
Cholecystokinin octapeptide (CCK-8): a negative feedback control mechanism for opioid analgesia.Prog Brain Res. 1995;105:263-71. doi: 10.1016/s0079-6123(08)63303-8. Prog Brain Res. 1995. PMID: 7568886 Review. No abstract available.
Cited by
-
Coordinated activity of a central pathway drives associative opioid analgesic tolerance.Sci Adv. 2023 Feb 10;9(6):eabo5627. doi: 10.1126/sciadv.abo5627. Epub 2023 Feb 8. Sci Adv. 2023. PMID: 36753548 Free PMC article.
-
Heteromerization of μ-opioid receptor and cholecystokinin B receptor through the third transmembrane domain of the μ-opioid receptor contributes to the anti-opioid effects of cholecystokinin octapeptide.Exp Mol Med. 2018 May 21;50(5):1-16. doi: 10.1038/s12276-018-0090-5. Exp Mol Med. 2018. PMID: 29780163 Free PMC article.
-
Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance.J Neurosci. 2005 Jan 12;25(2):409-16. doi: 10.1523/JNEUROSCI.4054-04.2005. J Neurosci. 2005. PMID: 15647484 Free PMC article.
-
CCK2 receptors in chronic pain.Neurobiol Pain. 2022 May 5;11:100092. doi: 10.1016/j.ynpai.2022.100092. eCollection 2022 Jan-Jul. Neurobiol Pain. 2022. PMID: 35571964 Free PMC article. Review.